Morgan Stanley analyst David Risinger said that Phase 2 data on Bristol-Myers’ oral TYK2 inhibitor BMS-986165 will be presented at the EADV meeting on Wednesday September 12, adding that it could be an underappreciated asset if it offers better efficacy than other oral drugs and is safer. To his knowledge, no JAK inhibitors are currently being developed for psoriasis, Risinger noted. The analyst, who said 986165 “theoretically has blockbuster potential,” maintains an Equal Weight rating on Bristol shares as further Opdivo lung newsflow is awaited.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.